checkAd
    Startseite > Aktien > Summit Therapeutics > Nachrichten
    Summit Therapeutics Aktie
    8,6850
     
    USD
    -20,47 %
    -2,2350 USD
    Letzter Kurs 01.06.24 Nasdaq
    8,6700
     
    USD
    200 STK
    Geldkurs 31.05.24
    8,6900
     
    USD
    300 STK
    Briefkurs 31.05.24
    ISIN: US86627T1088 · WKN: A2QDFS · SYM: SMMT · USA

    Neueste Nachrichten

    Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
    01.06.24 · Business Wire (engl.) · Summit Therapeutics
     Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
    01.06.24 · Business Wire (engl.) · Summit Therapeutics
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    31.05.24 · Business Wire (engl.) · Summit Therapeutics
    Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
    30.05.24 · Business Wire (engl.) · Summit Therapeutics
    Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
    01.05.24 · Business Wire (engl.) · Summit Therapeutics
    Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
    24.04.24 · Business Wire (engl.) · Summit Therapeutics
    Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
    11.04.24 · Business Wire (engl.) · Summit Therapeutics
    Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
    10.04.24 · Business Wire (engl.) · Summit Therapeutics
    Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
    22.03.24 · Business Wire (engl.) · Summit Therapeutics
    Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
    14.03.24 · Business Wire (engl.) · Summit Therapeutics
    Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
    05.03.24 · Business Wire (engl.) · Summit Therapeutics
    Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    26.02.24 · Business Wire (engl.) · Summit Therapeutics